AstraZeneca says FDA approves Etcamah-CDK4/6 combo for first-line advanced HR-positive breast cancer - AZN News | RalliesAstraZeneca says FDA approves Etcamah-CDK4/6 combo for first-line advanced HR-positive breast cancer
A
AZN• FDA approves Etcamah-CDK4/6 combination for first-line advanced HR-positive breast cancer
- FDA granted accelerated clearance for AstraZeneca’s Etcamah with a CDK4/6 inhibitor in first-line advanced HR-positive, HER2-negative breast cancer.
- Use targets patients who develop an emergent ESR1 mutation during aromatase inhibitor treatment, confirmed via an FDA-authorized test.
- SERENA-6 data showed a 56% lower risk of progression or death versus standard care; median PFS 16 months versus 9.2.
•
